UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
(Check One):_X_Form 10-K __Form 20-F __Form 11-K __Form 10-Q __ Form N-SAR
For Period Ended: ____June 30, 2000________
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended: _________________
If the notification relates to a portion of the filing checked
above, identify the item(s) to which the notification relates:
(PART I REGISTRANT INFORMATION)
Sangui Biotech International, Inc.
Full Name of Registrant
N/A
Former Name if Applicable
1508 Brookhollow Drive, Suite 354
Address of Principal Executive Officer (Street and Number)
Santa Ana, California 92705
City, State and Zip Code
PART II - RULES 12B-25(b) AND (c)
If the subject report could not be filed without unreasonable effort
of expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed. (Check box if
appropriate)
a) The reasons described in reasonable detail in Part II
of this form could not be eliminated without
unreasonable effort or expense;
_X_ b) The subject annual report, semi-annual report,
transition report on Form 10-K, Form 20-F, 11-K, Form
N-SAR, or portion thereof, will be filed on or before
the fifteenth calendar day following the prescribed due
date; or the subject quarterly report of transition
report on Form 10-Q, or portion thereof will be file on
or before the fifth calendar day following the
prescribed due date; and
c) The accountant's statement or other exhibit required by
Rule 12b-25(c) has been attached if applicable.
PART III NARRATIVE
State below in reasonable detail the reasons why the Form 10-K,
11-K, 10-Q, N-SAR, or the transition report or portion thereof,
could not be filed within the prescribed time period.
The Registrant was unable to file its Form 10-KSB within the
prescribed time period due to unanticipated delays in the completion
of the Registrant's audited financial statements for the period ended
June 30, 2000. The Registrant's financial statements for the applicable
period are being finalized and it is anticipated that the Registrant's
Form 10-KSB will be filed within 15 calendar days of the prescribed
due date.
PART IV OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to
this notification.
M. Richard Cutler (949) 719-1977
------------ ----- --------
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or
15(d)of the Securities Exchange Act of 1934 or Section 30 of the
Investment Company Act of 1940 during the preceding 12 months (or for
such shorter)period that the registrant was required to file such
reports) been filed? If answer is no, identify reports).
__X__ Yes ___ No
(3) Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal
year will be reflected by the earnings statements to be
included in the subject report or portion thereof?
___ Yes _X_ No
Sangui Biotech International, Inc.
_____________________________________________________________________
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: September 26, , 2000 By: /s/ Sieglinde Borchert
___________________________
Sieglinde Borchert, COO
